Good price  online

products details

Created with Pixso. Home Created with Pixso. Products Created with Pixso.
Chest Lung Cancer Drugs
Created with Pixso. Cabozantinib 60mg Tablets for Kidney Thyroid Liver Cancer Treatment

Cabozantinib 60mg Tablets for Kidney Thyroid Liver Cancer Treatment

Brand Name: Cabozanix
Model Number: XL-184
MOQ: 1 PCS
Price: Please contact a specialist WhatsApp:55342706
Delivery Time: Negotiable
Payment Terms: Western Union,MoneyGram,T/T
Detail Information
Place of Origin:
Bangladesh
Specifications::
60mg*30 Tablets/bottle/box
Indications:
Kidney Cancer, Thyroid Cancer, Liver Cancer, Soft Tissue Sarcoma, Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Bowel Cancer
Target:
RET、MET、VEGFR-1,2,3、KIT
Product Name:
Cabozantinib
Recommended Dose:
Please Follow Doctor's Advice
Storage:
Store Cabozantinib At 20°C To 25°C (68°F To 77°F); Excursions Allowed From 15°C To 30°C (59°F To 86°F).
Packaging Details:
Negotiable
Supply Ability:
Negotiable
Highlight:

skin endocrine rheumatism drugs wholesaler

,

wholesaler skin endocrine rheumatism drugs

,

wholesaler skin endocrine rheumatism drug

Product Description
Cabozantinib XL-184 (Cabozanix) 60mg Tablets
Product Specifications
Attribute Value
Specifications 60mg*30 tablets/bottle/box
Indications Kidney cancer, thyroid cancer, liver cancer, soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, bowel cancer
Target RET, MET, VEGFR-1,2,3, KIT
Recommended Dose Please follow doctor's advice
Storage Store at 20°C to 25°C (68°F to 77°F); excursions allowed from 15°C to 30°C (59°F to 86°F)
Description
Generic name: cabozantinib
Other names: cabozantinib/XL184
Indications
Treatment of progressive, unresectable locally advanced or metastatic medullary thyroid cancer and advanced kidney cancer that has failed Sutent.
Dosage and Administration
Recommended dosage: 60 mg daily. Do not take with food. Avoid eating for at least 2 hours before and 1 hour after taking.
Swallow tablets whole; do not crush. Continue treatment until clinical benefit ceases or unacceptable toxicity occurs.
Dosage Adjustments
  • Discontinue 28 days before scheduled surgery
  • For Grade 4 adverse reactions or intolerable Grade 2-3 reactions, withhold and reduce dose
  • Permanently discontinue for severe bleeding, arterial thromboembolic events, or uncontrolled hypertension
Warnings and Precautions
Bleeding: Serious bleeding occurred in 2.1% of patients. Do not use in patients with severe bleeding risk.
GI Perforation/Fistula: Reported in 0.9-1.2% of patients. Monitor closely and discontinue if occurs.
Thrombotic Events: Increased incidence of venous (7.3%) and arterial (0.9%) thromboembolism.
Hypertension: Occurred in 37% of patients (15% ≥ grade 3). Monitor blood pressure regularly.
Diarrhea: Occurred in 74% of patients (11% grade 3). Manage with antidiarrheals and dose reduction.
Adverse Reactions
Most common (≥25%): diarrhea, fatigue, nausea, anorexia, palmoplantar erythrodysesthesia syndrome (PPES), hypertension, vomiting, weight loss, constipation.
Special Populations
  • Pregnancy: May cause fetal harm. Use effective contraception during and for 4 months after treatment
  • Breastfeeding: Avoid during treatment and for 4 months after final dose
  • Hepatic Impairment: Reduce dose for mild-moderate impairment. Avoid in severe impairment
  • Elderly: No significant differences in safety/efficacy observed
Additional Information
Cabozantinib 60mg Tablets for Kidney Thyroid Liver Cancer Treatment 0